Traders Buy Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of unusually large options trading on Monday. Stock traders acquired 4,400 call options on the company. This represents an increase of approximately 37% compared to the typical volume of 3,206 call options.

Analyst Upgrades and Downgrades

A number of research firms have commented on CAPR. HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday. Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CAPR. Farallon Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter worth approximately $31,056,000. Vanguard Group Inc. lifted its stake in Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after acquiring an additional 700,243 shares in the last quarter. Woodline Partners LP purchased a new position in Capricor Therapeutics during the 4th quarter valued at about $8,693,000. Altium Capital Management LLC boosted its holdings in shares of Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after purchasing an additional 429,000 shares during the period. Finally, Black Diamond Financial LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth approximately $3,833,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $13.70 on Wednesday. The stock has a market capitalization of $622.94 million, a price-to-earnings ratio of -12.92 and a beta of 4.08. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a 50 day moving average price of $14.41 and a 200 day moving average price of $13.87.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.